At a glance Life sciences in London and the south east 02–03 MedCity At a glance: Life sciences in London and the south east Welcome The ‘golden triangle’ is the The golden triangle is being boosted world-leading life sciences cluster further by a wave of significant new of London, Oxford, Cambridge and investment, including: England’s greater south east. The Francis Crick Institute – At a glance: Life sciences in London bringing together 1,500 scientists and the south east has been created under one roof to help you navigate this exciting Imperial West – co-locating ecosystem. It provides a snapshot of researchers and businesses this evolving community, its current on 25 acres strengths and the plans for future UCL East – a cross-discipline investment and growth. enterprise and innovation centre focused on health and biological This cluster is a rich network of technologies on the site of renowned research centres, healthcare Queen Elizabeth Olympic Park providers and medical charities, The Institute of Cancer Research innovative SMEs and large industry – creating the world’s second largest players, all based within a compact and cancer research campus in south London well-connected geographical region. AstraZeneca’s Global R&D Centre – bringing together 2,000 employees in Cambridge This region is a hotbed of innovation, home to: To maximise this wave of new investment four of the world’s top MedCity was launched in April 2014. 10 universities This unique enterprise is your portal to five out of seven of the UK’s the diverse expertise, innovation and academic health science centres infrastructure of the region. Whether you leading medical research are looking for academic, healthcare or institutes including the Wellcome business partners, research infrastructure, Trust, the Medical Research office and incubator space or guidance Council, Cancer Research UK, and through tax and regulatory processes, the national Cell Therapy Catapult, MedCity is here to help. focusing on stem cell research Imperial West, co-locating world-class researchers, and industrialisation. medcitylondon.com businesses and higher education partners. +44 (0)20 7691 3588 04–05 MedCity 09 24 At a glance: Life sciences in London and the south east 115 CAMBRIDGE 88 16 91 64 39 67 118 36 Ipswich Stratford Camden Hackney Community 113 103 65 66 112 Hoxton M1 M11 Colchester 72 41 82 King’s Cross 89 17 Luton 117 57 76 10 8 115 106 58 56 116 93 45 07 95 35 59 10 4 38 The City OXFORD 23 18 97 15 114 71 10 5 37 98 92 51 29 80 M40 M25 Paddington 44 83 Whitechapel 10 0 Notting Hill 11 50 19 Mayfair 120 101 63 84 05 34 20 48 Westminster 90 102 119 08 79 10 28 122 87 Swindon 54 Kensington Canary Wharf 42 99 46 Waterloo 73 22 04 06 26 49 32 40 47 74 Bermondsey Hammersmith 94 M4 Reading 85 43 21 86 55 01 33 121 75 110 25 27 109 53 14 LONDON 02 Chelsea 111 60 12 13 81 31 Canterbury 68 52 61 Guildford 70 M25 M20 M3 30 78 62 Dover Fulham 96 03 77 69 Hastings 107 Southampton Brighton Portsmouth Commercial/R&D/Manufacturing Academic/Healthcare Agency 01–05 Abbott 33 Chugai Pharma 54 London East 82 Stevenage Biocatalyst 88 Cambridge University 98 Imperial College 109 –111 The Institute of 119 European Medicines 06 Abbvie 34 Daiichi Sankyo Science Park 83–84 Takeda Health Partners Academic Health Cancer Research Agency 07 Abcodia 35 Eisai 55 Merck Serono 85 UCB 89 Cancer Research UK Science Centre 112 The Royal 12 0 Medical Research 08 Allergan 36–37 Genzyme 56 Mitsubishi 86 UK BioIndustry 90 Cell Therapy Catapult 99 Imperial College London Veterinary College Council 09–11 Amgen 38–40 Gilead Sciences Tanabe Pharma Association 91 Genomic Medicine 100 Imperial West 113 UCL East 121 Medicines and 12 Association of the 41–43 GlaxoSmithKline 57 MRC Technology 87 Verona Pharma Centre East of England 101 King’s College London 114 UCLPartners Healthcare Products British Healthcare 44 GW Pharmaceuticals 58–59 MSD 92 Genomic Medicine 102 King’s Health Partners 115 University College Regulatory Agency Industries 45 Immodulon 60–61 Novartis Centre Imperial College 103 London BioScience London 122 National Institute for 13 Association of the Therapeutics 62 Novo Nordisk Health Partners Innovation Centre 115 University of Health Research British Pharmaceutical 46 ImmuPharma 63 OBN 93 Genomic Medicine 104 London School of Cambridge Industry 47 Imperial College 64 One Nucleus Centre Oxford Hygiene and 116 University of Oxford 14 Astellas Bio Incubator 65–70 Pfizer 94 Genomic Medicine Tropical Medicine 117 Wellcome Trust 15–17 AstraZeneca 48 Imperial College 71 Queen Mary Centre South London 105 Oxford Academic Health 118 Wellcome Trust 18–23 Baxter ThinkSpace Bio Enterprises 95 Genomic Medicine Science Centre Sanger Institute 24–25 Bayer 49 Ipsen 72–75 Quintiles Centre UCLPartners 106 Queen Mary University 26 Biogen Idec 50 Janssen 76–77 Roche 96 Genomic Medicine of London 27 Boehringer Ingelheim 51 Johnson & Johnson 78 Sanofi Centre Wessex 107 St. George’s, 28 Bristol-Myers Squibb Innovation Centre 79 Servier 97 Imanova University of London 29–31 BTG 52–53 Lilly 80 Shionogi Limited 108 The Francis Crick 32 Celgene 81 Shire Institute 06–07 MedCity At a glance: Life sciences in London and the south east A world-class centre Leading the for clinical research genomics revolution London is home to a highly diverse Clinical research within the National Launched in 2012, the UK-wide 100,000 Eleven genomic medicine centres have population supported by a large single Health Service is supported by the Genomes Project will sequence 100,000 now been set up to support the project, healthcare system that maintains National Institute for Health Research, genomes in four years; an immensely including five in London, Oxford and extensive patient records – over eight which provides: ambitious project that has never been done Cambridge. They are recruiting people million patients use the NHS in the on this scale anywhere in the world. with cancer or rare diseases and their a single point of contact for capital, over a third of whom were born families to take part in a project that industry studies outside the UK. By providing better insight into the will bring benefit to patients for years centralised and coordinated causes of diseases and how diseases to come. study feasibility assessment This concentration of diverse patient develop in each individual, genomics support with patient recruitment. groups in a small geography makes can be used to make medicine more genomicsengland.co.uk it easier and faster to set up complex It also runs the Coordinated System for tailored and personalised, minimising trials, and identify and recruit the right gaining NHS Permission (CSP), which unwanted side effects. patient groups working across primary streamlines the process of gaining care, general hospital and specialist permission to carry out clinical trials clinical services. within the NHS. 08–09 MedCity At a glance: Life sciences in London and the south east Financial strength Abcodia and the world’s largest clinical trial Case study The UK biotechnology, healthcare Over the past five years, the FTSE and life sciences industries offer a Healthcare Indices have significantly wide range of investment opportunities outperformed others, with the FTSE with diverse business models. All Share Healthcare Index rising by 10% in 2014, compared to a 3% drop 2014 saw robust levels of public market for the FTSE All Share. activity in healthcare, with £1.25bn ($1.9bn) raised in life sciences IPOs The UK has the largest pipeline of new and follow on offerings on the London pharmaceutical product candidates in Stock Exchange. Europe, with over 460 in 2013. University College London The trial also generated a biobank of spin-out Abcodia is commercialising 5.5 million serum samples that can technology licensed from be used to develop and test other Massachusetts General Hospital to diagnostics for early detection of develop the world’s first ovarian cancer cancer and other diseases of aging. diagnostic with accuracy high enough The serum is stored in the UK by to be applied to population screening. ThermoFisher. The test defines what a woman’s The clinical trial will report this healthy level of CA125, a substance in year. Results indicate that this test the blood, should be and detects the has huge potential to enable early rise early should ovarian cancer start diagnosis at a stage when women to develop. It has been validated in the are not showing any symptoms of the world’s largest prospective clinical trial, disease, hopefully leading to improved which recruited over 202,000 women survival rates. over 10 years and is managed by University College London. 10 –11 MedCity At a glance: Life sciences in London and the south east Pfizer and the rare Useful contacts diseases consortium Case study London & Partners Healthcare centres Clinical trials support London & Partners are the Cambridge University National Institute for experts on doing business Health Partners Health Research in London, helping overseas cuhp.org.uk nihr.ac.uk businesses set up and grow in the capital. Imperial College Academic Membership organisations Health Science Centre +44 (0)20 7234 5800 ahsc.org.uk BioIndustry Association [email protected] bioindustry.org invest.london King’s Health Partners @L_PBusiness kingshealthpartners.org OBN obn.org.uk Academic centres Oxford Academic Health Science Network One Nucleus University of Cambridge oxfordahsn.org onenucleus.com cam.ac.uk UCLPartners Imperial College London uclpartners.com imperial.ac.uk Research institutes King’s College London kcl.ac.uk Cell Therapy Catapult Better therapies for rare diseases are Analysis of patients’ genomes allows ct.catapult.org.uk the target of a consortium made up researchers to identify the pathways University of Oxford of Pfizer, the University of Cambridge, that cause disease, enabling the ox.ac.uk Francis Crick Institute crick.ac.uk Imperial College London, King’s targeted design of new treatments.